TY - JOUR
T1 - Patient perspectives on the use of digital medical devices and health data for AI-driven personalised medicine in Parkinson’s Disease
AU - Paccoud, Ivana
AU - Valero, Mayca Marín
AU - Marín, Laura Carrasco
AU - Bontridder, Noémi
AU - Ibrahim, Alzhraa
AU - Winkler, Jüergen
AU - Fomo, Messaline
AU - Sapienza, Stefano
AU - Khoury, Fouad
AU - Corvol, Jean Christophe
AU - Fröhlich, Holger
AU - Klucken, Jochen
N1 - Funding:
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Luxembourg National Research Fund: (dHealthPD: 14146272) and the ERA PerMed EU-wide project DIGIPD (01KU2110).
Publisher Copyright:
Copyright © 2024 Paccoud, Valero, Marín, Bontridder, Ibrahim, Winkler, Fomo, Sapienza, Khoury, Corvol, Fröhlich and Klucken.
PY - 2024/12/4
Y1 - 2024/12/4
N2 - Introduction: Parkinson’s Disease (PD) affects around 8.5 million people currently with numbers expected to rise to 12 million by 2040. PD is characterized by fluctuating motor and non-motor symptoms demanding accurate monitoring. Recent advancements in digital medical devices (DMDs) like wearables and AI offer promise in addressing these needs. However, the successful implementation of DMDs in healthcare relies on patients’ willingness to adopt and engage with these digital tools. Methods: To understand patient perspectives in individuals with PD, a cross-sectional study was conducted as part of the EU-wide DIGIPD project across France, Spain, and Germany. Multidisciplinary teams including neurodegenerative clinics and patient organizations conducted surveys focusing on (i) sociodemographic information, (ii) use of DMDs (iii) acceptance of using health data (iv) preferences for the DMDs use. We used descriptive statistics to understand the use of DMDs and patient preferences and logistic regression models to identify predictors of willingness to use DMDs and to share health data through DMDs. Results: In total 333 individuals with PD participated in the study. Findings revealed a high willingness to use DMDs (90.3%) and share personal health data (97.4%,) however this differed across sociodemographic groups and was more notable among older age groups (under 65 = 17.9% vs. over 75 = 39.29%, p = 0.001) and those with higher education levels less willing to accept such use of data (university level = 78.6% vs. 21.43% with secondary level, p = 0.025). Providing instruction on the use of DMDs and receiving feedback on the results of the data collection significantly increased the willingness to use DMDs (OR = 3.57, 95% CI = 1.44–8.89) and (OR = 3.77, 95% CI = 1.01–14.12), respectively. Conclusion: The study emphasizes the importance of considering patient perspectives for the effective deployment of digital technologies, especially for older and more advanced disease-stage patients who stand to benefit the most.
AB - Introduction: Parkinson’s Disease (PD) affects around 8.5 million people currently with numbers expected to rise to 12 million by 2040. PD is characterized by fluctuating motor and non-motor symptoms demanding accurate monitoring. Recent advancements in digital medical devices (DMDs) like wearables and AI offer promise in addressing these needs. However, the successful implementation of DMDs in healthcare relies on patients’ willingness to adopt and engage with these digital tools. Methods: To understand patient perspectives in individuals with PD, a cross-sectional study was conducted as part of the EU-wide DIGIPD project across France, Spain, and Germany. Multidisciplinary teams including neurodegenerative clinics and patient organizations conducted surveys focusing on (i) sociodemographic information, (ii) use of DMDs (iii) acceptance of using health data (iv) preferences for the DMDs use. We used descriptive statistics to understand the use of DMDs and patient preferences and logistic regression models to identify predictors of willingness to use DMDs and to share health data through DMDs. Results: In total 333 individuals with PD participated in the study. Findings revealed a high willingness to use DMDs (90.3%) and share personal health data (97.4%,) however this differed across sociodemographic groups and was more notable among older age groups (under 65 = 17.9% vs. over 75 = 39.29%, p = 0.001) and those with higher education levels less willing to accept such use of data (university level = 78.6% vs. 21.43% with secondary level, p = 0.025). Providing instruction on the use of DMDs and receiving feedback on the results of the data collection significantly increased the willingness to use DMDs (OR = 3.57, 95% CI = 1.44–8.89) and (OR = 3.77, 95% CI = 1.01–14.12), respectively. Conclusion: The study emphasizes the importance of considering patient perspectives for the effective deployment of digital technologies, especially for older and more advanced disease-stage patients who stand to benefit the most.
KW - acceptance of digital medical devices
KW - Adoption of AI
KW - Parkinson’s Disease
KW - patient preferences
KW - patient-centeredness
KW - personalized medicine
KW - trust
KW - use of health data
UR - http://www.scopus.com/inward/record.url?scp=85212248690&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/39697442/
U2 - 10.3389/fneur.2024.1453243
DO - 10.3389/fneur.2024.1453243
M3 - Article
C2 - 39697442
AN - SCOPUS:85212248690
SN - 1664-2295
VL - 15
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 1453243
ER -